Articles: disease.
-
Eur. J. Obstet. Gynecol. Reprod. Biol. · Feb 1993
Multicenter StudyPreliminary report of unexpected local reactions to a progestogen-releasing contraceptive vaginal ring.
This is the first report of vaginal erythematous areas associated with the use of a levonorgestrel-releasing contraceptive ring. Of 139 female subjects, 48 developed lesions of varying size and degrees of redness. Sixteen of these have undergone serial colposcopy and thirteen have also had biopsy examinations, which revealed acetowhite areas and, histologically, chronic inflammation with widely dilated vessels and frequently with thinning of the epithelium. The cause remains uncertain but hormonal, chemical and physical effects might all have a role.
-
Br J Obstet Gynaecol · Aug 1992
Randomized Controlled Trial Multicenter Study Clinical TrialGenital tract infections associated with the intrauterine contraceptive device can be reduced by inserting the threads into the uterine cavity.
To study the influence of the position of the threads of an intrauterine contraceptive device (IUCD) on the development of genital tract infection. ⋯ Infectious complications in women using an IUCD are more frequent if the threads lead from the uterine cavity to the vagina. This problem can be reduced by inserting the threads so that they remain entirely within the uterine cavity, a feasible procedure now that an effective instrument for IUCD thread retrieval is available.
-
Australas. J. Dermatol. · Jan 1991
Multicenter Study Comparative Study Clinical Trial Controlled Clinical TrialAn open study of Triphasil and Diane 50 in the treatment of acne.
Levonorgestrel, as used in oral contraceptives, has antiovulatory activity at doses far lower than those producing androgenic effects. Triphasil, containing levonorgestrel was compared with Diane, containing cyproterone acetate in a trial of acne treatment. Twenty closely matched patients were alternatively allocated to 6 months of Triphasil or Diane treatment. ⋯ Assays of total testosterone, androgen index, free testosterone, dehydroepiandrosterone sulphate and androstenedione showed significant reduction on treatment and sex hormone binding globulin was raised. All hormonal changes were more marked in the Diane group. Side effects caused only one withdrawal from the trial.